All patients | POCs | No POCs | p-value | |
Patients | 28 (100) | 8 (29) | 20 (71) | |
Age yrs | 53±16 | 52±18 | 54±15 | 0.76 |
PH type | ||||
Idiopathic PAH | 10 (36) | 3 (37) | 7 (35) | |
Associated PAH¶ | 10 (36) | 4 (50) | 6 (30) | 0.44 |
CTEPH | 8 (28) | 1 (13) | 7 (35) | |
Specific therapy | ||||
No | 12 (43) | 4 (50) | 8 (40) | 0.69 |
Yes | 16 (57) | 4 (50) | 12 (60) | |
Oral therapy alone | 9 | 0 | 9 | |
Bosentan+ | 10 | 0 | 10 | |
Sildenafil+ | 2 | 1 | 1 | |
Epoprostenol+ | 5 | 3 | 2 | |
Other prostanoids§ | 2 | 1 | 1 | |
CCBs | 1 | 0 | 1 | |
NYHA class | ||||
I–II | 21 (75) | 4 (50) | 17 (80) | 0.14 |
III | 7 (25) | 4 (50) | 3 (20) | |
6MWD m | 388±114 | 311±140 | 411±99 | 0.058 |
Haemodynamics | ||||
P̄pa mmHg | 43±12 | 44±13 | 43±12 | 0.77 |
Pra mmHg | 6.3±4.0 | 6.2±4.1 | 6.3±3.9 | 0.93 |
Ppcw mmHg | 9.0±3.0 | 9.3±3.9 | 8.6±2.7 | 0.59 |
CI L·min−1·m−2 | 3.25±0.68 | 3.28±0.52 | 3.24±0.75 | 0.89 |
SVI mL·m−2 | 42±10 | 38±8 | 43±10 | 0.25 |
PVRI WU·m−2 | 11.1±5.7 | 10.0±4.6 | 11.5±6.1 | 0.60 |
Sv,O2 %ƒ | 66±6 | 71±6 | 64±6 | 0.05 |
Data are presented as n (%), mean±sd or n, unless otherwise stated. POC: perioperative complication; PAH: pulmonary arterial hypertension; CTEPH: chronic thromboembolic pulmonary hypertension; CCB: calcium channel blocker; NYHA: New York Heart Association; 6MWD: 6-min walking distance; P̄pa: mean pulmonary arterial pressure; Pra: right atrial pressure; Ppcw: pulmonary capillary wedge pressure; CI: cardiac index; SVI: stroke volume index; PVRI: indexed pulmonary vascular resistance; WU: Wood unit; Sv,O2: mixed venous oxygen saturation. #: up to day 28; ¶: comprising five portopulmonary hypertension, three connective tissue disease-associated PAH and two HIV-associated PAH patients; +: includes patients on combination therapy; §: including beraprost and iloprost; ƒ: n = 18.